Sat, Jul 26, 2014, 3:57 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Guidant Corporation (New) (GDT) Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • serious_investor serious_investor Dec 23, 1997 7:04 PM Flag

    Impact of AVE stent approval on GDT?

    Thanks, exStentman, this is beginning to make sense to me. Based on the following:

    >I've mentioned before in my postings: AVE and GDT will snag the lion share of the coronary stent (USA) market in 1998, with GDT probably getting more than less because of its powerful franchise of other product lines.<

    how do the other competitors retaliate; i.e., Cordis and MDT?

    Also, if GDT decides to bundle their products to compete against AVEI, how will BSX and Cordis respond; that is, aren't they both at risk of losing a major portion of their balloon business if customers opt for GDT's bundle?

    Do you see this turning into a pricing war?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • >how do the other competitors retaliate; i.e., Cordis and MDT?<

      Cordis just got FDA approval yesterday for their CROWN. Has not overwhelmed the European market, but is arguably better than PS. Analysts don't see this as a threat to GDT/AVE.

      Cordis has sued AVE for patent infringement. Cordis and MDT have cross licensed each other. Implies MDT has some patent position too, yes? This remains a wild card.

      MDT has beStent in clinical trials in the US, and the Wiktor commercially available. I don't see beStent in the US for at least a year, and Wiktor is not competitive with GDT/AVE.

      > Also, if GDT decides to bundle their products to compete against AVEI, how will BSX and Cordis respond; that is,
      aren't they both at risk of losing a major portion of their balloon business if customers opt for GDT's bundle? <

      yes

      > Do you see this turning into a pricing war? <

      Perhaps in bundles, where you pay for the stent system, but get a free balloon, or free wire, or one price for several menu
      items, etc. I don't think you'll see major price concessions on the stent itself, at least not initially. I could be wrong here.
      It'll be difficult to track - expect at least a quarter before we hear of any trends. Don't forget - AVE offers LONG STENTS. So if
      you implant ONE LONG STENT where indicated, it might be much cheaper than implanting two PS Stents, or two Multilinks etc...
      This will become very muddy as I don't know each company's pricing strategies. Fun to speculate though.

 

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.